Vaccine experts mull booster shots for 'special population' | Inquirer News

Vaccine experts mull booster shots for ‘special population’

/ 02:42 PM July 29, 2021

San Juan City residents get inoculated with a single dose of Johnson & Johnson's at the FilOil Flying V Center

San Juan City residents get inoculated with a single dose of Johnson & Johnson’s at the FilOil Flying V Center on Wednesday, July 21, where around 600 individuals from A2-A3 priority categories recieved the one-shot vaccine. Niño Jesus Orbeta/Philippine Daily Inquirer

MANILA, Philippines — The Department of Science and Technology’s (DOST) Vaccine Expert Panel (VEP) is mulling to recommend giving COVID-19 booster shots to a “special population” or those whose antibody response to vaccines is low due to certain medical conditions.

VEP head Dr. Nina Gloriani said the panel has been meeting “lengthily” about booster shots, following reports that some vaccines have lesser effects against the Delta and other variants of COVID-19.

Article continues after this advertisement

“We were in a meeting yesterday and in the past lengthily all about booster shots. Yes we are looking at that possibility especially with these reports of waning immunity but we are looking more at a special population,” she told an online media forum when asked if the panel is considering the administration of booster shots.

FEATURED STORIES

According to Gloriani, studies abroad have shown that available vaccines in the country have reduced efficacy against the Delta variant but continue to provide protection against the severe form of the disease.

However, VEP member Dr. Rontgene Solante said that the panel is looking at providing booster shots only to people whose antibody response to two doses of COVID-19 vaccine is low.

Article continues after this advertisement

“Ito ang tinitingnan namin na kung meron mang kailangan ng booster, doon natin ibibigay sa special population na medyo mababa ang antibody response nila sa mga bakuna,” he said.

Article continues after this advertisement

(If ever we will need booster shots, we are looking at providing it to a special population who have low antibody response to vaccines.)

Article continues after this advertisement

Solante said these are people with human immunodeficiency virus, cancer, the elderly, and those taking Immunosuppressive drugs after receiving organ transplants especially for chronic kidney diseases.

“These are the possible populations that the VEP will hopefully recommend kung kailangan nating i-booster (if ever we will need booster shots), over the general population,” Solante said.

Article continues after this advertisement

The Department of Health (DOH) earlier said it is open to administering COVID-19 booster shots to people with compromised immune systems as long as there is evidence for its safety and efficacy.

However, it maintained that experts do not recommend administering booster shots at present due to lack of sufficient evidence for its safety and because of limited vaccine supply.

EDV
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: coronavirus Philippines, COVID-19

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.